menu
    • menu
    [{"orgOrder":0,"company":"Bridge Medicines","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Bridge Medicines","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Bridge Medicines \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Bridge Medicines \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Bridge Medicines","sponsor":"Bridge Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"UBR5","graph1":"Oncology","graph2":"Preclinical","graph3":"Bridge Medicines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bridge Medicines \/ Bridge Medicines","highestDevelopmentStatusID":"4","companyTruncated":"Bridge Medicines \/ Bridge Medicines"},{"orgOrder":0,"company":"Bridge Medicines","sponsor":"Galecto","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"BRM-1420","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Bridge Medicines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bridge Medicines \/ Galecto","highestDevelopmentStatusID":"4","companyTruncated":"Bridge Medicines \/ Galecto"}]

    Find Clinical Drug Pipeline Developments & Deals by Bridge Medicines

    Menu

    Bridge Medicines

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Bridge Medicines

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Bridge Medicines

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BRM-1420

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Galecto

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Galecto Focuses on Oncology, Acquires Leukemia Asset from Bridge Medicines

                            Details : Galecto has bolstered its pipeline with the acquisition of the global rights to BRM-1420, a novel dual ENL-YEATS and FLT3 inhibitor of multiple genetic subsets of AML, developed by Bridge Medicines.

                            Brand Name : BRM-1420

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 07, 2024

                            Lead Product(s) : BRM-1420

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Galecto

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Bridge Medicines

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Bridge Medicines

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Cornell University

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Bridge License Agreement with Cornell University for UBR5 Inhibitor Program

                            Details : UBR5 is a cellular enzyme (an E3 ubiquitin ligase) that is involved in the labeling of other proteins within a cell to designate them for destruction.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 28, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Cornell University

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Bridge Medicines

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Bridge Medicines

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : $10.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Bridge Medicines Announces Additional Funding of $10 Million from Inside Investors

                            Details : Bridge Medicines is currently developing novel inhibitors of ENL-YEATS for the treatment of acute leukemias and a series of orally active small molecule inhibitors of activated factor XII for the treatment of hereditary angioedema and other inflammatory ...

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            November 12, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : $10.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth